Das, S.; Ailawadhi, S.; Sher, T.; Roy, V.; Fernandez, A.; Parrondo, R.D.
Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Curr. Oncol. 2023, 30, 9627-9633.
https://doi.org/10.3390/curroncol30110697
AMA Style
Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD.
Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Current Oncology. 2023; 30(11):9627-9633.
https://doi.org/10.3390/curroncol30110697
Chicago/Turabian Style
Das, Saurav, Sikander Ailawadhi, Taimur Sher, Vivek Roy, Andre Fernandez, and Ricardo D. Parrondo.
2023. "Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety" Current Oncology 30, no. 11: 9627-9633.
https://doi.org/10.3390/curroncol30110697
APA Style
Das, S., Ailawadhi, S., Sher, T., Roy, V., Fernandez, A., & Parrondo, R. D.
(2023). Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Current Oncology, 30(11), 9627-9633.
https://doi.org/10.3390/curroncol30110697
